Dermaseptin Peptide Derivatives Kill MDR Klebsiella and Staph at Low Concentrations

Four dermaseptin S4 and B2 derivatives showed antibacterial activity against MDR K. pneumoniae and S. epidermidis with MICs of 6.25-25 μg/mL and concentration-dependent cytotoxicity.

Haddad, Houda et al.·Biochemistry and biophysics reports·2026·
RPEP-152482026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Four dermaseptin derivatives (K4K20S4, K4S4(1-16), B2, K3K4B2) showed MICs 6.25-25 μg/mL and MBCs 12.5-50 μg/mL against MDR K. pneumoniae and S. epidermidis, with concentration-dependent cytotoxicity.

Key Numbers

How They Did This

Synthesis of four dermaseptin S4/B2 derivatives, MIC/MBC determination against MDR K. pneumoniae and S. epidermidis, and cytotoxicity assessment via MTT assay on HEp-2 cells.

Why This Research Matters

K. pneumoniae and S. epidermidis cause devastating hospital infections with increasingly limited antibiotic options. Frog-derived peptide alternatives could fill this gap.

The Bigger Picture

Frog skin remains one of nature's richest sources of antimicrobial peptides, with dermaseptins showing consistently promising activity against hospital superbugs.

What This Study Doesn't Tell Us

In vitro only. Therapeutic window between antimicrobial and cytotoxic concentrations needs optimization. In vivo efficacy not tested.

Questions This Raises

  • ?Can the therapeutic window be improved through further sequence optimization?
  • ?Would these derivatives show activity against other ESKAPE pathogens?
  • ?What is the mechanism of action enabling dual Gram-positive/negative activity?

Trust & Context

Key Stat:
6.25-25 μg/mL MIC Frog-derived peptide derivatives effective against two major MDR hospital pathogens at therapeutically relevant concentrations
Evidence Grade:
Standard in vitro AMP characterization. Promising activity levels needing in vivo validation.
Study Age:
Published in 2025.
Original Title:
Antibacterial activity of peptide derivatives of dermaseptins against multidrug-resistant Klebsiella pneumoniae and Staphylococcus epidermis.
Published In:
Biochemistry and biophysics reports, 45, 102449 (2026)
Database ID:
RPEP-15248

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What are dermaseptins?

Antimicrobial peptides naturally produced in frog skin. They evolved over millions of years to protect frogs from skin infections and show potent activity against bacteria that resist human antibiotics.

Can frog peptides treat human infections?

In the lab, yes — these derivatives kill two of the most dangerous hospital bacteria at low concentrations. Further development is needed to create formulations suitable for treating human infections.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-15248·https://rethinkpeptides.com/research/RPEP-15248

APA

Haddad, Houda; Al-Rashidi, Reyadh R; Loghmari, Ahmed; Sahtout, Wissal; Boukadida, Raja; Dahmene, Rihem; Ettouil, Emeny; Othman, Houcemeddine; Ouahchi, Ines; Zaϊri, Amira. (2026). Antibacterial activity of peptide derivatives of dermaseptins against multidrug-resistant Klebsiella pneumoniae and Staphylococcus epidermis.. Biochemistry and biophysics reports, 45, 102449. https://doi.org/10.1016/j.bbrep.2026.102449

MLA

Haddad, Houda, et al. "Antibacterial activity of peptide derivatives of dermaseptins against multidrug-resistant Klebsiella pneumoniae and Staphylococcus epidermis.." Biochemistry and biophysics reports, 2026. https://doi.org/10.1016/j.bbrep.2026.102449

RethinkPeptides

RethinkPeptides Research Database. "Antibacterial activity of peptide derivatives of dermaseptin..." RPEP-15248. Retrieved from https://rethinkpeptides.com/research/haddad-2026-antibacterial-activity-of-peptide

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.